| abstract |
The application provides a bifunctional compound of formula (I): a targeting ligand which acts as a proteolysis-inducing moiety for EGFR and / or a mutant thereof. The present application also links the ubiquitin ligase junction with a ligand capable of binding to EGFR and / or a mutant thereof, which can be used in the treatment of disorders modulated by EGFR or mutants thereof. Methods are described for the targeted degradation of EGFR and / or mutants thereof by use of a bifunctional compound. [Chem. 1] [C.] None |